CHU

Morphocell Technologies Announces a New Stem Cell Process That May Pave Way for Liver Cell Therapy and Drug Development

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Pharmaceutical, Health, Stem Cells, Immunosuppression, Stem Cell Reports, Toxicity, Clinical trial, 2D, Liver transplantation, Patient, Stem Cell Network, Regeneration, Liver, Potency (pharmacology), Hepatocyte, Liver failure, CHU, 3D, Drug development, Institute of Liver and Biliary Sciences, Canadian Institutes of Health Research, Partnership, Cell, Medical imaging, Pharmaceutical industry

Researchers discovered a high-yield method to produce high-quality liver cells (hepatoblasts and hepatocytes) from pluripotent stem cells.

Key Points: 
  • Researchers discovered a high-yield method to produce high-quality liver cells (hepatoblasts and hepatocytes) from pluripotent stem cells.
  • Moreover, the cells produced with this process have the potential to be developed into treatments for several liver diseases.
  • The work was supported by the Stem Cell Network and the Canadian Institutes for Health Research, in partnership with Morphocell Technologies Inc.
  • Founded in 2018, Morphocell is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating severe liver diseases.

OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

Retrieved on: 
Monday, November 15, 2021
Mnemos EP, SITC, Macrophage, Cancer, Boehringer Ingelheim, Mab, Tissue, Center, Ulcerative colitis, Myelocyte, Immune system, Veloxis Pharmaceuticals, T cell, Immunology, Autoimmune disease, Severe acute respiratory syndrome coronavirus 2, B cell, Society, Nivolumab, COVID-19, Fortification, Immunotherapy, Research, Tumor microenvironment, Inflammation, PD-1, Phagocytosis, IL-7, CHU, Epitope, AACR, Partnership, Society for Immunotherapy of Cancer, ISIN, OSE, Annual general meeting, GLOBE, Large-cell lung carcinoma, Antibody, Degenerative disease, INSERM, Mouse, Vaccination, Pancreatic cancer, Patient, Drug development, Vaccine, Pharmaceutical industry

CLEC-1 is a new myeloid checkpoint inhibitor identified and validated for cancer immunotherapy after the CD47-SIRP pathway, which is now a competitive drug development focus.

Key Points: 
  • CLEC-1 is a new myeloid checkpoint inhibitor identified and validated for cancer immunotherapy after the CD47-SIRP pathway, which is now a competitive drug development focus.
  • CLEC-1 suppress dendritic cell antigen presentation and is a novel myeloid immune checkpoint target for cancer immunotherapy.
  • CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy controlling damaged and tumor cells phagocytosis.
  • CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.

EBR Systems’ WiSE CRT System Demonstrates Technical Feasibility of Leadless Left Bundle Branch Area Pacing for Cardiac Resynchronization

Retrieved on: 
Wednesday, October 27, 2021
Cardiology, Biotechnology, Medical Supplies, Hardware, Health, Medical Devices, Technology, Other Health, Coronary sinus, Technology, CHU, Cardiac resynchronization therapy, Bradycardia, CRT, ECG, EBR, Nasal septum, European Heart Journal, LV, CEO, Silicon, Atrioventricular block, Male, Hope, Wireless, Heart failure, Wise, Heart, Elbogen, Sale, Medical device

EBR Systems, Inc. , developer of the worlds only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating the WiSE CRT Systems ability to successfully deliver leadless Left Bundle Branch Area Pacing (LBBAP).

Key Points: 
  • EBR Systems, Inc. , developer of the worlds only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating the WiSE CRT Systems ability to successfully deliver leadless Left Bundle Branch Area Pacing (LBBAP).
  • WiSE is the only leadless pacing technology able to achieve LBBAP, a novel form of conduction system pacing which can reverse left bundle branch block and deliver cardiac resynchronization therapy (CRT).
  • WiSE is the first and only leadless pacing system that can deliver physiologic, conduction system pacing without leads.
  • Cardiac Resynchronization Therapy by Left Bundle Branch Area Pacing in Patients with Heart Failure and Left Bundle Branch Block.

Antimicrobial button LIBU’s efficiency confirmed in deactivating the influenza virus

Retrieved on: 
Wednesday, September 29, 2021
CL3, Infection, Center, Student, Disinfectant, Containment, Virus, Fonds, Electronics, Associate, Technology, COVID-19, GRB, CHU, Viral load, UVC, GLOBE, Animal, Vaccine

This study evaluated the effectiveness of LIBUs Ultraviolet-C technology in disinfecting elevator buttons contaminated with the H1N1 influenza virus responsible for the 2009 pandemic.

Key Points: 
  • This study evaluated the effectiveness of LIBUs Ultraviolet-C technology in disinfecting elevator buttons contaminated with the H1N1 influenza virus responsible for the 2009 pandemic.
  • We have developed a technique to assess the effectiveness of UV-C light for decontaminating elevator buttons infected with seasonal influenza virus.
  • Each button was inoculated with high concentrations of the pandemic H1N1 influenza virus.
  • The self-disinfecting LIBU elevator button allows to "retrofit" existing control panels as well as being adapted to new control panels.

DGAP-News: Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR

Retrieved on: 
Monday, September 27, 2021
ISIN, European Association of Nuclear Medicine, Oncology, PET, European Medicines Agency, University Hospital (Newark, New Jersey), Deutsch, ISS, Multiple myeloma, Bone marrow, Centre Hospitalier Universitaire Grenoble Alpes, European Association for the Study of the Liver, CXCR4, III, News, Therapy, Cancer, Patient, Death, DGAP, Association, Nuclear medicine, TecDAX, FDG-PET, Lymphoma, Lymphatic system, Teaching hospital, Disease, B cell, FDG, CHU, Research, IRON, Society, Security (finance), Medical imaging, Pharmaceutical industry

The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.

Key Points: 
  • The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.
  • To investigate the potential of PENTIXAFOR the CHU will recruit, on its own account, up to 45 patients in a so-called investigator-initiated study (ISS).
  • Given the potential of PENTIXAFOR for improved patient stratification, academic groups like CHU have decided to move ahead on their own and to test PENTIXAFOR right away.
  • To speed up the PENTIXAFOR marketing authorization, Eckert & Ziegler closely cooperates with such initiatives and supports them where feasible.

DGAP-News: Abivax presents first-half 2021 financial results and operations update

Retrieved on: 
Thursday, September 23, 2021
ISIN, CEST, International Advisory and Monitoring Board, Population, Licensure, Program, EST, Methotrexate, Safety, Investment, EMA, DSMB, Research, JAK, MTX, Crohn's disease, Twitter, Bristol Myers Squibb, Hepatocellular carcinoma, Ulcerative colitis, MicroRNA, Maintenance, CHU, Headache, Operating cost, Chemokine, Clinical trial, Inflammatory Bowel Diseases, Probability, USD, Observation, Inflammation, FDA, Cancer, Nausea, Company, HCC, Scripps, Rheumatoid arthritis, CD, ITT, G&A, IBD, MD Anderson Cancer Center, ACR20, Cytokine, COVID-19, Patient, Trial of the century, Nivolumab, Degenerative disease, Film, Pharmaceutical industry, Animal, Birth control, Medical device, Poultry

2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.

Key Points: 
  • 2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.
  • Cash at the end of June 2021 was EUR 4.3M, compared to EUR 29.3M at the end of 2020, before taking into account the EUR 85M financing realized in July 2021.
  • In March 2021, Abivax announced it would be stopping the phase 2b/3 Covid-19 study (miR-AGE trial - ABX464-401) due to lack of efficacy.
  • Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors.

Great Lakes Grain completes 12th Crop Assessment Tour – 2021 Yield and Quality Report

Retrieved on: 
Tuesday, September 7, 2021

CHATHAM, Ontario, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Great Lakes Grain has concluded their annual Crop Assessment Tour, now in its twelfth year.

Key Points: 
  • CHATHAM, Ontario, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Great Lakes Grain has concluded their annual Crop Assessment Tour, now in its twelfth year.
  • Don Kabbes, Great Lakes Grain General Manager, says, The tour allows us to observe crop performance for our customers.
  • The Great Lakes Grain Crop Assessment Tour has been conducted yearly since 2010 to assess the size of the Ontario crop, as well as gives growers a better understanding of how their crop is performing compared to others in the province.
  • This years corn crop is estimated to yield higher than last years crop, it will likely be a new provincial yield record.